Emergent Biosolutions Stock Current Valuation

EBS Stock

USD 6.78 0.39 5.44%

Valuation analysis of Emergent Biosolutions helps investors to measure Emergent Biosolutions' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to gain to 30.47 in 2025. Enterprise Value Multiple is likely to gain to 30.47 in 2025. Fundamental drivers impacting Emergent Biosolutions' valuation include:

Price Book

0.7041

Enterprise Value

905.8 M

Enterprise Value Ebitda

8.5937

Price Sales

0.4031

Forward PE

47.8469

Undervalued

Today

6.78

Please note that Emergent Biosolutions' price fluctuation is moderately volatile at this time. Calculation of the real value of Emergent Biosolutions is based on 3 months time horizon. Increasing Emergent Biosolutions' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.

Buy or Sell Advice Valuation Matrix

The fair value of the Emergent stock is determined by what a typical buyer is willing to pay for full or partial control of Emergent Biosolutions. Since Emergent Biosolutions is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Emergent Stock. However, Emergent Biosolutions' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.

Historical

Market 6.78

Real 8.13

Target 13.5

Hype 6.8

Naive 6.5

The intrinsic value of Emergent Biosolutions' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Emergent Biosolutions' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.

1.62

Downside

8.13

Real Value

Target Odds

Above Odds

Below Odds

14.64

Upside

Estimating the potential upside or downside of Emergent Biosolutions helps investors to forecast how Emergent stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Emergent Biosolutions more accurately as focusing exclusively on Emergent Biosolutions' fundamentals will not take into account other important factors:

Earnings

Estimates (0)

Low	Projected	High
0.19	0.25	0.30

Details

Hype

Prediction

Low	Estimated	High
0.29	6.80	13.31

Details

Naive

Forecast

Low	Next Value	High
0.13	6.50	13.01

Details

3 Analysts

Consensus

Low	Target Price	High
12.29	13.50	14.99

Details

Emergent Biosolutions Company Current Valuation Analysis

Emergent Biosolutions' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Emergent Biosolutions Current Valuation

905.77 M

Most of Emergent Biosolutions' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Emergent Biosolutions is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Emergent Current Valuation Driver Correlations

Understanding the fundamental principles of building solid financial models for Emergent Biosolutions is extremely important. It helps to project a fair market value of Emergent Stock properly, considering its historical fundamentals such as Current Valuation. Since Emergent Biosolutions' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Emergent Biosolutions' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Emergent Biosolutions' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Good Will	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Current Deferred Revenue	Long Term Debt	Short Term Investments	Property Plant Equipment	Deferred Long Term Liab	Treasury Stock	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.94	0.67	0.45	0.6	0.62	0.63	0.96	0.64	0.48	0.69	0.64	0.72	0.8	0.74	0.96	0.72	-0.52	0.82	0.82	0.8	0.1	0.54	0.91	0.2	0.09
Total Stockholder Equity	0.94		0.4	0.54	0.45	0.53	0.41	0.81	0.55	0.33	0.48	0.42	0.74	0.67	0.55	0.97	0.57	-0.33	0.7	0.69	0.65	-0.09	0.62	0.83	0.37	0.17
Net Debt	0.67	0.4		-0.12	0.51	0.54	0.76	0.81	0.39	0.49	0.8	0.77	0.31	0.75	0.9	0.51	0.8	-0.77	0.74	0.74	0.83	0.41	-0.07	0.71	-0.28	-0.35
Retained Earnings	0.45	0.54	-0.12		0.59	0.5	0.3	0.34	0.73	0.22	0.37	0.26	0.53	0.1	-0.04	0.51	-0.03	0.22	0.12	0.17	-0.01	-0.21	0.8	0.43	0.41	0.61
Accounts Payable	0.6	0.45	0.51	0.59		0.81	0.86	0.66	0.91	0.3	0.85	0.83	0.7	0.54	0.6	0.45	0.47	-0.38	0.61	0.58	0.55	0.04	0.45	0.67	0.24	0.11
Net Receivables	0.62	0.53	0.54	0.5	0.81		0.85	0.64	0.72	0.02	0.84	0.81	0.7	0.68	0.62	0.5	0.47	-0.22	0.6	0.72	0.57	-0.33	0.17	0.59	0.39	0.12
Good Will	0.63	0.41	0.76	0.3	0.86	0.85		0.74	0.76	0.23	0.97	0.98	0.6	0.73	0.8	0.42	0.65	-0.49	0.73	0.77	0.72	0.08	0.14	0.65	0.16	-0.11
Total Liab	0.96	0.81	0.81	0.34	0.66	0.64	0.74		0.65	0.55	0.79	0.77	0.64	0.82	0.82	0.86	0.77	-0.62	0.85	0.85	0.84	0.23	0.44	0.89	0.06	0.03
Total Current Assets	0.64	0.55	0.39	0.73	0.91	0.72	0.76	0.65		0.41	0.75	0.74	0.67	0.47	0.49	0.57	0.43	-0.37	0.6	0.51	0.51	0.13	0.66	0.7	0.27	0.12
Short Term Debt	0.48	0.33	0.49	0.22	0.3	0.02	0.23	0.55	0.41		0.34	0.31	-0.05	0.03	0.28	0.49	0.27	-0.58	0.35	0.05	0.41	0.76	0.43	0.51	-0.65	0.16
Intangible Assets	0.69	0.48	0.8	0.37	0.85	0.84	0.97	0.79	0.75	0.34		0.94	0.56	0.73	0.8	0.51	0.66	-0.48	0.69	0.76	0.71	0.13	0.2	0.74	0.08	-0.06
Common Stock	0.64	0.42	0.77	0.26	0.83	0.81	0.98	0.77	0.74	0.31	0.94		0.57	0.7	0.82	0.45	0.67	-0.59	0.8	0.74	0.79	0.16	0.15	0.64	0.1	-0.1
Current Deferred Revenue	0.72	0.74	0.31	0.53	0.7	0.7	0.6	0.64	0.67	-0.05	0.56	0.57		0.72	0.57	0.66	0.52	-0.22	0.67	0.75	0.55	-0.3	0.52	0.68	0.69	0.04
Long Term Debt	0.8	0.67	0.75	0.1	0.54	0.68	0.73	0.82	0.47	0.03	0.73	0.7	0.72		0.88	0.67	0.84	-0.5	0.79	0.99	0.78	-0.06	0.14	0.77	0.38	-0.32
Short Term Investments	0.74	0.55	0.9	-0.04	0.6	0.62	0.8	0.82	0.49	0.28	0.8	0.82	0.57	0.88		0.59	0.87	-0.77	0.88	0.86	0.91	0.26	0.07	0.8	0.08	-0.45
Property Plant Equipment	0.96	0.97	0.51	0.51	0.45	0.5	0.42	0.86	0.57	0.49	0.51	0.45	0.66	0.67	0.59		0.63	-0.45	0.72	0.68	0.69	0.08	0.63	0.87	0.21	0.13
Deferred Long Term Liab	0.72	0.57	0.8	-0.03	0.47	0.47	0.65	0.77	0.43	0.27	0.66	0.67	0.52	0.84	0.87	0.63		-0.77	0.82	0.82	0.86	0.25	0.07	0.73	0.1	-0.43
Treasury Stock	-0.52	-0.33	-0.77	0.22	-0.38	-0.22	-0.49	-0.62	-0.37	-0.58	-0.48	-0.59	-0.22	-0.5	-0.77	-0.45	-0.77		-0.79	-0.46	-0.83	-0.65	-0.05	-0.6	0.31	0.5
Net Tangible Assets	0.82	0.7	0.74	0.12	0.61	0.6	0.73	0.85	0.6	0.35	0.69	0.8	0.67	0.79	0.88	0.72	0.82	-0.79		0.8	0.97	0.19	0.27	0.76	0.18	-0.24
Long Term Debt Total	0.82	0.69	0.74	0.17	0.58	0.72	0.77	0.85	0.51	0.05	0.76	0.74	0.75	0.99	0.86	0.68	0.82	-0.46	0.8		0.78	-0.09	0.19	0.76	0.4	-0.22
Capital Surpluse	0.8	0.65	0.83	-0.01	0.55	0.57	0.72	0.84	0.51	0.41	0.71	0.79	0.55	0.78	0.91	0.69	0.86	-0.83	0.97	0.78		0.25	0.12	0.75	0.01	-0.31
Short Long Term Debt	0.1	-0.09	0.41	-0.21	0.04	-0.33	0.08	0.23	0.13	0.76	0.13	0.16	-0.3	-0.06	0.26	0.08	0.25	-0.65	0.19	-0.09	0.25		0.14	0.27	-0.68	-0.35
Cash And Equivalents	0.54	0.62	-0.07	0.8	0.45	0.17	0.14	0.44	0.66	0.43	0.2	0.15	0.52	0.14	0.07	0.63	0.07	-0.05	0.27	0.19	0.12	0.14		0.56	0.32	0.38
Net Invested Capital	0.91	0.83	0.71	0.43	0.67	0.59	0.65	0.89	0.7	0.51	0.74	0.64	0.68	0.77	0.8	0.87	0.73	-0.6	0.76	0.76	0.75	0.27	0.56		0.15	-0.16
Net Working Capital	0.2	0.37	-0.28	0.41	0.24	0.39	0.16	0.06	0.27	-0.65	0.08	0.1	0.69	0.38	0.08	0.21	0.1	0.31	0.18	0.4	0.01	-0.68	0.32	0.15		0.05
Capital Stock	0.09	0.17	-0.35	0.61	0.11	0.12	-0.11	0.03	0.12	0.16	-0.06	-0.1	0.04	-0.32	-0.45	0.13	-0.43	0.5	-0.24	-0.22	-0.31	-0.35	0.38	-0.16	0.05

Click cells to compare fundamentals

Emergent Current Valuation Historical Pattern

Today, most investors in Emergent Biosolutions Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Emergent Biosolutions' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Emergent Biosolutions current valuation as a starting point in their analysis.

Emergent Biosolutions Current Valuation

Timeline

Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Competition

Predict Emergent Biosolutions

Enterprise Value Over Time

In accordance with the recently published financial statements, Emergent Biosolutions has a Current Valuation of 905.77 M. This is 93.69% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 94.55% higher than that of the company.

Emergent Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Emergent Biosolutions' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Emergent Biosolutions could also be used in its relative valuation, which is a method of valuing Emergent Biosolutions by comparing valuation metrics of similar companies.

Emergent Biosolutions is currently under evaluation in current valuation category among its peers.

Emergent Biosolutions ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Emergent Biosolutions' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Emergent Biosolutions' managers, analysts, and investors.

Environmental

Governance

Social

Emergent Fundamentals

	Return On Equity	-0.22
	Return On Asset	-0.0161
	Profit Margin	(0.14) %
	Operating Margin	0.23 %
	Current Valuation	905.77 M
	Shares Outstanding	54.28 M
	Shares Owned By Insiders	2.82 %
	Shares Owned By Institutions	66.85 %
	Number Of Shares Shorted	9.06 M
	Price To Earning	1.67 X
	Price To Book	0.70 X
	Price To Sales	0.40 X
	Revenue	1.01 B
	Gross Profit	354 M
	EBITDA	36.9 M
	Net Income	(190.6 M)
	Cash And Equivalents	99.5 M
	Cash Per Share	7.28 X
	Total Debt	663.7 M
	Debt To Equity	0.56 %
	Current Ratio	3.92 X
	Book Value Per Share	10.14 X
	Cash Flow From Operations	58.7 M
	Short Ratio	6.12 X
	Earnings Per Share	(2.58) X
	Price To Earnings To Growth	1.55 X
	Target Price	13.5
	Number Of Employees	900
	Beta	2.09
	Market Capitalization	389.17 M
	Total Asset	1.39 B
	Retained Earnings	(212.4 M)
	Working Capital	436.3 M
	Current Asset	537.41 M
	Current Liabilities	99.61 M
	Net Asset	1.39 B

About Emergent Biosolutions Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Emergent Biosolutions's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emergent Biosolutions using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emergent Biosolutions based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Emergent Stock Analysis

When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Emergent Biosolutions Stock Current Valuation

Emergent Biosolutions Company Current Valuation Analysis

Enterprise Value

Market Cap + Debt

-

Cash

Current Emergent Biosolutions Current Valuation

Emergent Current Valuation Driver Correlations

Emergent Current Valuation Historical Pattern

Emergent Current Valuation Peer Comparison

Emergent Biosolutions ESG Sustainability

Emergent Fundamentals

About Emergent Biosolutions Fundamental Analysis

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Emergent Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY